GlassScriptPhysician profile
Megan Johnson
NPI 1245042688
$393.07
in general payments reported to CMS, 2019-2025
13 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $63.69 | 2025 | General - Erectile Dysfunction, Lithovue |
| Urogen Pharma, INC. | $56.03 | 2025 | |
| Pfizer INC. | $39.00 | 2025 | |
| Abiomed | $36.34 | 2025 | |
| Merck Sharp & Dohme LLC | $35.56 | 2025 | Keytruda, Keytruda Qlex |
| Accord Healthcare, INC. | $27.40 | 2025 | |
| Antares Pharma, INC. | $23.47 | 2025 | Xyosted |
| Procept Biorobotics Corporation | $21.75 | 2025 | |
| Sumitomo Pharma America, INC. | $20.44 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $20.34 | 2025 | |
| Dendreon Pharmaceuticals LLC | $18.21 | 2025 | Provenge |
| Progenics Pharmaceuticals, INC. | $16.60 | 2025 | Pylarify |
| Endo USA, INC. | $14.24 | 2025 | Xiaflex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.